Recently there has been some rancor in CGM land as many have asked why Tandem decided to work with Abbott when they already have a perfectly good relationship with Dexcom. Rancor which will get louder now that Tandem has released the results from the DCLP3 study which found – per a Tandem press release-
“Over the six-month study period, use of Control-IQ technology led to a higher percentage of time spent in range (70-180 mg/dL), less hyper- and hypoglycemia and better HbA1c levels than use of a sensor augmented pump. No severe hypoglycemic events were reported, and . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.